Лекарственно-индуцированная мочекаменная болезнь
- Авторы: Листратов А.И1, Остроумова О.Д1,2, Литвинова С.Н1
-
Учреждения:
- Российская медицинская академия непрерывного профессионального образования
- Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)
- Выпуск: Том 29, № 6 (2022)
- Страницы: 30-36
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/321010
- DOI: https://doi.org/10.18565/pharmateca.2022.6.30-36
- ID: 321010
Цитировать
Полный текст
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Полный текст
Об авторах
А. И Листратов
Российская медицинская академия непрерывного профессионального образованияМосква, Россия
О. Д Остроумова
Российская медицинская академия непрерывного профессионального образования; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)
Email: ostroumova.olga@mail.ru
д.м.н., профессор, зав. кафедрой терапии и полиморбидной патологии, Российская медицинская академия непрерывного профессионального образования; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) Москва, Россия
С. Н Литвинова
Российская медицинская академия непрерывного профессионального образованияМосква, Россия
Список литературы
- Клинические рекомендации. Мочекаменная болезнь. Минздрав России, Общероссийская общественная организация «Российское общество урологов». Пересмотр 2020 г. @@Clinical guidelines. Kidney stone disease. Health Ministry of Russia, Russian Society of Urology. Revision 2020. (In Russ.). URL: https://cr.minzdrav.gov.ru/recomend/7_1
- Lopez M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol. 2010;25(1):49-59. doi: 10.1007/s00467-008-0960-5.
- Scales C.D. Jr., Smith A.C., Hanley J.M., Saigal C.S.; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-65. Doi: 10.1016/j. eururo.2012.03.052.
- Ramello A, Vitale C., Marangella M. Epidemiology of nephrolithiasis. J Nephrol. 2000;13 Suppl 3:45-50.
- Romero V, Akpinar H., Assimos D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-96.
- Fink H.A., Wilt T.J., Eidman K.E., et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-43. doi: 10.7326/0003-4819-158-7-201304020 00005.
- Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. doi: 10.1155/2018/3068365.
- Song L., Maalouf N.M. Nephrolithiasis. [Updated 2020 Mar 9]. In: Feingold K.R., Anawalt B., Boyce A., et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279069/
- Dobrek t. Kidney stone disease with special regard to drug-induced kidney stones - a contemporary synopsis. Wiad Lek. 2020;73(9 cz. 2):2031-2039. doi: 10.36740/WLek202009226.
- Tisdale J.E., Miller D.A. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018. 1399 p.
- Daudon M., Frochot V., Bazin D., Jungers P Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs. 2018;78(2):163-201. doi: 10.1007/s40265-017-0853-7.
- Albala D.M., Prien E.L. Jr, Galal H.A. Urolithiasis as a hazard of sulfonamide therapy. J Endourol. 1994;8(6):401-3. Doi: 10.1089/ end.1994.8.401.
- Garnier A.S., Dellamaggiore J., Brilland B., et al. High Incidence of Amoxicillin-Induced Crystal Nephropathy in Patients Receiving High Dose of Intravenous Amoxicillin. J Clin Med. 2020;9(7):2022. doi: 10.3390/jcm9072022.
- Christakos A., Bowen D.K., Doolin E.J., et al. Case report: Ampicillin-induced stone formation causing bilateral ureteral obstruction during pelvic surgery. Urol Case Rep. 2019;24:100851. doi: 10.1016/j.eucr.2019.100851.
- Avci Z., Koktener A., Uras N., et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004;89(11):1069- 72. Doi: 10.1136/
- Mohkam M., Karimi A., Gharib A., et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007;22(5):690-doi: 10.1007/s00467-006-0401-2.
- Chopra N., Fine P.L., Price B., Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol. 2000;164(2):438.
- Olivera M.E., Allemandi D.A., Manzo R.H.Intrinsic dissolution rate and intestinal permeability of metallic complexes of norfloxacin and ciprofloxacin in relation to their formulation. Acta Farm. Bonaerense. 2000;19:185-191.
- Daudon M., Reveilland R.J., Laurence C., Guenel J. Drug-induced oxolinic acid crystalluria and nephrolithiasis. Clin Nephrol. 1987;28(3):156.
- Saltel E., Angel J.B., Futter N.G., et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895-97.
- de Lastours V., Ferrari Rafael De Silva E., Daudon M., et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-56. doi: 10.1093/jac/dkt125.
- Maurice-Estepa L., Daudon M., Katlama C., et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32(3):392-400. Doi: 10.1053/ ajkd.1998.v32.pm9740154.
- Jick H., Dinan B.J., Hunter J.R. Triamterene and renal stones. J Urol. 1982;127(2):224-5. doi: 10.1016/s0022-5347(17)53708-8.
- Lee M.H., Lee Y.H., Hsu T.H., et al. Silica stone-development due to long time oral trisilicate intake. Scand J Urol Nephrol. 1993;27(2):267-69. doi: 10.3109/00365599309181263.
- Hasan M.N., Tiselius H.G. Mesalamine: a rare constituent of urinary tract concretions. Urolithiasis. 2013;41(3):271-72. Doi: 10.1007/ s00240-013-0553-z.
- Maalouf N.M., Langston J.P, Van Ness P.C., et al. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303-7. doi: 10.1007/s00240-010-0347-5.
- Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765-73. doi: 10.1185/030079907X210499.
- Sigg T, Leikin J.B. Massive crystalluria in a patient taking primidone. Ann Emerg Med. 1999;33(6):726-27. doi: 10.1016/s0196-0644(99)80022-5.
- Cranefield D.J., Odd D.E., Harding J.E., Teele R.L. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. Pediatr Radiol. 2004;34(2):138-42. doi: 10.1007/s00247-003-1090-7.
- Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-683. doi: 10.1056/NEJMoa055218.
- Traxer O, Huet B., Poindexter J., et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol. 2003;170(2 Pt 1):397-401. doi: 10.1097/01.ju.0000076001.21606.53.
- Scozzafava A., Supuran C.T. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349-59. doi: 10.1007/978-94-007-73 59-2_17.
- Gimpel C, Krause A., Franck P., et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int. 2010;52(1):51-6. doi: 10.1111/J.1442- 200X.2009.02886.x.
- Kranen S., Keough D., Gordon R.B., Emmerson B.T. Xanthine-containing calculi during allopurinol therapy. J Urol. 1985;133(4):658-59. doi: 10.1016/s0022-5347(17)49133-6.
- Huynh J., Hever A., Tom T., Sim J.J. Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy.Int Urol Nephrol. 2011;43(2):571-73. Doi: 10.1007/ s11255-010-9751-6.
- Daudon M., Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245-75. doi: 10.2165/00003495-200464030-00003.
- Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24:767-8.
- Dawson C.H., Tomson C.R. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med (Lond). 2012;12(5):467--71. doi: 10.7861/clinmedicine.12-5-467.
- Evan A.P Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25(5):831-41. doi: 10.1007/s00467-009-1116-y.
- Cloutier J., Villa L., Traxer O., Daudon M. Kidney stone analysis: "Give me your stone, I will tell you who you are!". World J Urol. 2015;33(2):157-doi: 10.1007/s00345-014-1444-9.
- Rapado A., Traba M.L., Caycho C., Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol. 1987;58:25-9. doi: 10.1159/000414481.
- Sakhaee K., Maalouf N.M., Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847-60. Doi: 10.1210/ jc.2011-3492.
- Barbas C., Garcia A., Saavedra L., Muros M. Urinary analysis of nephrolithiasis markers. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781(1-2):433-55. doi: 10.1016/s1570-0232(02)00557-3.
- Сычев Д.А., Остроумова О.Д., Переверзев А.П. и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;27(6):113-26. @@Sychev D.A., Ostroumova O.D., Pereverzev A.P., et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateca. 2020;27(6):113-26. (In Russ.) Doi: 10.18565/ pharmateca.2020.6.113-26.
- Cohen-Solal F., Abdelmoula J., Hoarau M.P, et al. Urinary lithiasis of medical origin [in French]. Therapie. 2001;56(6):743-50.
- Nadler R.B., Rubenstein J.N., Eggener S.E, et al. The etiology of urolithiasis in HIV infected patients. J Urol. 2003;169(2):475-77. doi: 10.1097/01.ju.0000046021.43205.d6.
- Izzedine H., Lescure F.X., Bonnet F HIV medication-based urolithiasis. Clin Kidney J. 2014;7(2):121-26. doi: 10.1093/ckj/sfu008.
- Borghi L., Meschi T., Maggiore U., Prati B. Dietary therapy in idiopathic nephrolithiasis. Nutr Rev 2006;64(7 Pt 1):301-12. Doi: 10.1301/ nr.2006.jul.301-312.
- Pearle M.S., Goldfarb D.S., Assimos D.G., et al.; American Urological Assocation. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-24. Doi: 10.1016/j. juro.2014.05.006.
- Meschi T., Maggiore U., Fiaccadori E., et al. The effect of fruits and vegetables on urinary stone risk factors. Kidney Int. 2004;66(6):2402-10. doi: 10.1111/j.1523-1755.2004.66029.x.